News 2023-06-23
Porton Pharma Solutions Launches State-of-the-Art Small Molecule Platform in Shanghai, Elevating CDMO Services
We are thrilled to announce the establishment of our state-of-the-art Small Molecule Platform in Shanghai, revolutionizing our CDMO services. With this exciting development, Porton Pharma Solutions Ltd. now have seven R&D and production facilities in Shanghai that are equipped to provide comprehensive solutions for drug substance, drug preparation, synthetic macromolecules, and biological macromolecules.
As a trusted partner in the pharmaceutical industry, we understand the evolving needs of our clients and the importance of seamless integration throughout the drug development process. With our Small Molecule Platform, we offer a one-stop-shop solution, combining our expertise, cutting-edge facilities, and advanced technologies to accelerate and streamline the development of small molecule-based therapeutics.
This groundbreaking development reinforces our commitment to be at the forefront of CDMO services and empower our clients with the tools and expertise needed to succeed in the fast-paced pharmaceutical landscape. We are excited to collaborate with innovators, researchers, and pharmaceutical companies to drive scientific advancements, improve patient outcomes, and shape the future of healthcare.
Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.

News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.